Virus-based immunotherapy biotech Transgene is to begin clinical trials of its head and neck cancer drug candidate TG4050 after gaining regulatory clearance from the UK regulator.<
Merck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Bristol-Myers Squibb, with positive results in kidney cancer, and the promise of an F
Kisaco Research’s CAR-T Congress EU could not have come at a better time – the day after it finished NICE announced it had granted funding for a new use for Novartis’ cancer cell therapy Ky
Getting CAR-T cells to work in solid tumours is proving a tough nut to crack – and a conference heard details of a cutting-edge approach that could inform clinical trials in the future.
AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication
Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabet
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.